144 related articles for article (PubMed ID: 28120478)
1. Potency and stability of compounded formulations of chlorambucil, melphalan and cyclophosphamide.
Burton JH; Knych HK; Stanley SD; Rebhun RB
Vet Comp Oncol; 2017 Dec; 15(4):1558-1563. PubMed ID: 28120478
[TBL] [Abstract][Full Text] [Related]
2. Frequency and Severity of Neutropenia Associated with Food and Drug Administration Approved and Compounded Formulations of Lomustine in Dogs with Cancer.
Burton JH; Stanley SD; Knych HK; Rodriguez CO; Skorupski KA; Rebhun RB
J Vet Intern Med; 2016; 30(1):242-6. PubMed ID: 26682700
[TBL] [Abstract][Full Text] [Related]
3. Potency and stability of compounded cyclophosphamide: a pilot study.
Robat C; Budde J
Vet Comp Oncol; 2017 Sep; 15(3):706-709. PubMed ID: 27028306
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of drug content (potency) for compounded and FDA-approved formulations of doxycycline on receipt and after 21 days of storage.
KuKanich K; KuKanich B; Slead T; Warner M
J Am Vet Med Assoc; 2017 Oct; 251(7):835-842. PubMed ID: 28967825
[TBL] [Abstract][Full Text] [Related]
5. Drug compounding for veterinary patients.
Papich MG
AAPS J; 2005 Sep; 7(2):E281-7. PubMed ID: 16353910
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of the Most Frequently Prescribed Extemporaneously Compounded Veterinary Medications at a Large Independent Community Pharmacy.
Karara AH; Hines R; Demir Z; Nnorom B; Horsey R; Twigg G
Int J Pharm Compd; 2016; 20(6):461-467. PubMed ID: 28339384
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of compounded aqueous milbemycin oxime: issues with formulation potency and reproducibility.
Cochrane ZN; Berger DJ; Viall AK; Schrunk D; Hans Coetzee JF
J Small Anim Pract; 2019 Jan; 60(1):27-31. PubMed ID: 29998573
[TBL] [Abstract][Full Text] [Related]
8. Analysis of lomustine drug content in FDA-approved and compounded lomustine capsules.
KuKanich B; Warner M; Hahn K
J Am Vet Med Assoc; 2017 Feb; 250(3):322-326. PubMed ID: 28117638
[TBL] [Abstract][Full Text] [Related]
9. Stability and consistency of compounded oral liquid levothyroxine formulations.
Meyer LM; Stephens K; Carter CA; Pickard W; Johnson PR; Eagerton DH
J Am Pharm Assoc (2003); 2020; 60(6):e168-e172. PubMed ID: 32591200
[TBL] [Abstract][Full Text] [Related]
10. Variable accuracy, precision, and consistency of compounded famciclovir formulated for management of feline herpesvirus-1 in cats.
O'Leary LM; Allbaugh RA; Schrunk DE; Olsen TE; Sebbag L
Vet Ophthalmol; 2021 Nov; 24(6):627-638. PubMed ID: 34117694
[TBL] [Abstract][Full Text] [Related]
11. Drug content on receipt and over time for compounded formulations of famciclovir.
Johnson LR; Weaver PG; Forsythe LE; Thomasy SM; Knych HK
J Feline Med Surg; 2021 Jun; 23(6):519-525. PubMed ID: 33019848
[TBL] [Abstract][Full Text] [Related]
12. Carcinogenic potency of alkylating agents in rodents and humans.
Dedrick RL; Morrison PF
Cancer Res; 1992 May; 52(9):2464-7. PubMed ID: 1568217
[TBL] [Abstract][Full Text] [Related]
13. Compounding for animal patients: contemporary issues.
Lust E
J Am Pharm Assoc (2003); 2004; 44(3):375-84; quiz 384-6. PubMed ID: 15191248
[TBL] [Abstract][Full Text] [Related]
14. Accuracy and precision of compounded ciclosporin capsules and solution.
Umstead ME; Boothe DM; Cruz-Espindola C; Macdonald JM; Kennis R; Angarano D
Vet Dermatol; 2012 Oct; 23(5):431-e82. PubMed ID: 22970897
[TBL] [Abstract][Full Text] [Related]
15. Comparison of the Lonidamine Potentiated Effect of Nitrogen Mustard Alkylating Agents on the Systemic Treatment of DB-1 Human Melanoma Xenografts in Mice.
Nath K; Nelson DS; Putt ME; Leeper DB; Garman B; Nathanson KL; Glickson JD
PLoS One; 2016; 11(6):e0157125. PubMed ID: 27285585
[TBL] [Abstract][Full Text] [Related]
16. Comparative pharmacokinetics of chlorambucil and melphalan in man.
Alberts DS; Chang SY; Chen HS; Larcom BJ; Evans TL
Recent Results Cancer Res; 1980; 74():124-31. PubMed ID: 7444135
[TBL] [Abstract][Full Text] [Related]
17. Lomustine and melphalan cannot be replaced by cyclophosphamide and etoposide without reducing efficacy in MOPPEBVCAD chemotherapy for advanced Hodgkin's disease.
Gobbi PG; Broglia C; Bertè R; Petrilli MP; Molica S; Angrilli F; Iannitto E; Ghirardelli ML; Di Renzo N; Cavanna L; Ascari E
Haematologica; 2000 Jul; 85(7):722-8. PubMed ID: 10897124
[TBL] [Abstract][Full Text] [Related]
18. Long-term Stability of a Compounded Suspension of Torsemide (5 mg/mL) for Oral Administration.
Adin D; Johnson PR; Kim CH; Nguyenba T; Rosen S
J Vet Intern Med; 2017 Nov; 31(6):1822-1826. PubMed ID: 28913839
[TBL] [Abstract][Full Text] [Related]
19. Veterinary compounding in small animals: a clinical pharmacologist's perspective.
Boothe DM
Vet Clin North Am Small Anim Pract; 2006 Sep; 36(5):1129-73, viii. PubMed ID: 16984830
[TBL] [Abstract][Full Text] [Related]
20. Extemporaneous compounding in veterinary practice: a New Zealand perspective.
Gargiulo DA; Chemal C; Joda L; Lee YJ; Pilkington M; Haywood A; Garg S
N Z Vet J; 2013 Nov; 61(6):311-5. PubMed ID: 23544952
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
